12:00 AM
Jul 23, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Avonex interferon beta-1a: Postmarketing study data

The study included patients with RRMS from the British Columbia MS database. The treated cohort comprised patients exposed to interferon beta who first became eligible for treatment between July 1995 and December 2004. The contemporary control cohort comprised patients first eligible in the same period who remained unexposed to interferon beta, while the historical control cohort included patients eligible prior to the approval of interferon beta (April 1985-June 1995) who remained unexposed to interferon beta during the...

Read the full 361 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >